《新股表現》瑞科生物(02179.HK)暗盤低開4.8%報23.6元
根據輝立交易平臺顯示,明天掛牌的江蘇瑞科生物-B(02179.HK)暗盤低開4.8%報23.6元獲承接,最高見24.8元,現報24元,較上市價24.8元,低3.2%,成交5.3萬股。
瑞科是內地一家於2021年創立的疫苗公司,其主要專注於HPV候選疫苗的研發。是次上市以每股24.8元合共發售3,085.45萬股,並已引入包括揚子江香港、Harvest、SCHP及紅杉資本中國轄下Sequoia Capital China Growth四名基石投資,合共認購1,671.85萬股;其中10%公開發售獲9.65倍超購,認購一手中籤率9.28%;料集資淨額約6.72億元,其中約47.3%將用於HPV疫苗管線的研發、生產和商業化;約17.7%及21.1%將分別用於新冠肺炎候選疫苗(即ReCOV)及其他候選疫苗的臨牀前及臨牀研究、註冊。上市聯席保薦人分別爲大摩、招銀國際及中信證券。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.